Who are cisplatin or carboplatin + pemetrexed's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cisplatin-or-carboplatin-pemetrexed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

cisplatin or carboplatin + pemetrexed — Competitive Intelligence Brief

cisplatin or carboplatin + pemetrexed (cisplatin or carboplatin + pemetrexed) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy + antifolate antimetabolite combination. Area: Oncology.

phase 3 Platinum-based chemotherapy + antifolate antimetabolite combination DNA (platinum agents); thymidylate synthase, dihydrofolate reductase, GARFT (pemetrexed) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

cisplatin or carboplatin + pemetrexed (cisplatin or carboplatin + pemetrexed) — Immutep S.A.S.. This combination uses platinum-based chemotherapy (cisplatin or carboplatin) plus pemetrexed, a folate antagonist that inhibits multiple enzymes in nucleotide synthesis, to damage cancer cell DNA and disrupt cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cisplatin or carboplatin + pemetrexed TARGET	cisplatin or carboplatin + pemetrexed	Immutep S.A.S.	phase 3	Platinum-based chemotherapy + antifolate antimetabolite combination	DNA (platinum agents); thymidylate synthase, dihydrofolate reductase, GARFT (pemetrexed)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy + antifolate antimetabolite combination class)

Immutep S.A.S. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cisplatin or carboplatin + pemetrexed — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-or-carboplatin-pemetrexed. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab